← All drugs
Drug · FAERS side-effect profile with label screen

Brompheniramine side effects: what 320 FDA adverse event reports show

Brompheniramine Maleate, Dextromethorphan Hydrobromide · 6 reaction terms · 184 drug–reaction co-reports · data 2026-09-14
Share: X Facebook Reddit Email

Drug class

Not stated in label

Label matched

Brompheniramine Maleate, Dextromethorphan Hydrobromide (Childrens Cold And Cough)

closest FDA label found for this product string; brand list suppressed because the label is a related product, not an exact match

Who reports

320 reports · 81% serious · 22 with death outcome · 57% female

openFDA FAERS counts, all years, deduplication not applied

Used for

• temporarily relieves cough due to minor throat and bronchial irritation occurring with a cold • temporarily relieves these symptoms due to hay fever (allergic rhinitis): • runny nose • sneezing • itchy, watery eyes • itching of the nose or throat

FDA label, Indications and Usage

Boxed warning

None in the current label

How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation. Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)? That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.

Causality screen of the 5 strongest signals

No label text to screen 5
What the badges mean

Strongest disproportionality signals

Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only and flags pairs whose reports are unusually skewed by sex or come mostly from consumers rather than clinicians. 1 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.

Show:
ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Subarachnoid haemorrhage1170.6
39.5–126.3ROR 73.1 · χ² 687 / p 1e-151
63.2 EB05 37.7 · IC025 +3.1
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious PRR 50.2no trial data cached
Hemiparesis1557.7
35.2–94.6ROR 60.5 · χ² 780 / p 6e-172
53.9 EB05 34.7 · IC025 +3.5
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious PRR 41.4no trial data cached
Cerebrovascular accident (stroke)12347.4
41.3–54.5ROR 76.4 · χ² 5,586 / p <1e-300
47.1 EB05 40.5 · IC025 +5.0
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious PRR 34.0no trial data cached
Convulsion (seizure)2326.0
17.5–38.5ROR 27.9 · χ² 529 / p 2e-117
25.5 EB05 17.9 · IC025 +3.4
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious PRR 19.0no trial data cached
Cerebral infarction924.1
12.7–45.9ROR 24.8 · χ² 177 / p 1e-40
22.7 EB05 12.1 · IC025 +2.3
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious PRR 17.2no trial data cached

Trial evidence (ClinicalTrials.gov)

Trial cross-check not yet run for this drug (ClinicalTrials.gov pull covers the 800 most-reported drugs first).

Most frequently reported reactions

By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.

ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Cerebrovascular accident (stroke)12347.4
41.3–54.5ROR 76.4 · χ² 5,586 / p <1e-300
47.1 EB05 40.5 · IC025 +5.0
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious PRR 34.0no trial data cached
Convulsion (seizure)2326.0
17.5–38.5ROR 27.9 · χ² 529 / p 2e-117
25.5 EB05 17.9 · IC025 +3.4
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious PRR 19.0no trial data cached
Hemiparesis1557.7
35.2–94.6ROR 60.5 · χ² 780 / p 6e-172
53.9 EB05 34.7 · IC025 +3.5
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious PRR 41.4no trial data cached
Subarachnoid haemorrhage1170.6
39.5–126.3ROR 73.1 · χ² 687 / p 1e-151
63.2 EB05 37.7 · IC025 +3.1
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious PRR 50.2no trial data cached
Cerebral infarction924.1
12.7–45.9ROR 24.8 · χ² 177 / p 1e-40
22.7 EB05 12.1 · IC025 +2.3
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious PRR 17.2no trial data cached
Brain neoplasm321.4
6.9–66.0ROR 21.6 · χ² 40 / p 1e-10
12.5 EB05 2.8 · IC025 +0.4
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious PRR 15.5no trial data cached

Unlabeled candidate signals

Every screened signal with n ≥ 20 was either labeled, an indication term, or an artifact pattern — no unlabeled candidate stood out in the top signals.

Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.

Common questions

What are the most reported side effects of Brompheniramine?

In FDA FAERS, the most frequently co-reported reaction terms for Brompheniramine are cerebrovascular accident, convulsion, hemiparesis, subarachnoid haemorrhage, cerebral infarction, brain neoplasm. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.

Does Brompheniramine have an FDA boxed warning?

No. The FDA label retrieved for Brompheniramine has no boxed warning; see the label's Warnings and Precautions for the recognised risks.

Do FAERS signals prove that Brompheniramine causes these side effects?

No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.

Sources & methods

Page generated 2026-10-08. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.